Investment in the northeast Ohio biomedical sector totaled nearly $294 million in 2018 with 71 regional companies receiving funding, according to regional healthcare trade group BioEnterprise. Those figures make this region the third largest for total healthcare investment in the Midwest, following Minneapolis ($664 million) and Chicago ($551 million). These were among the findings of […]
Athersys Inc.
New FDA rules imperil Bioject | Wall Street Beat
Boston Scientific’s Alair asthma treatment gets a thumbs-up | Regulatory Roundup
VCs press Senate on “IPO On Ramp” bill | Wall Street Beat
The National Venture Capital Assn. is spearheading a drive to get a bill through the U.S. Senate that would make it easier for small companies to raise money by going public.
The "IPO On Ramp" measure would ease the regulatory requirements for IPOs and temporarily reduce the reporting burdens imposed by the Sarbanes-Oxley Act.
iRobot invests $6M into telemedicine company | Funding Roundup
iRobot Corp. (NSDQ: IRBT), famous for their Roomba automated cleaning robots, invested $6 million and launched an extended partnership with InTouch Health, which develops telemedicine systems for providing remote health care.
The venture builds on an existing relationship that the companies announced last summer, under which the companies engaged in a development and licensing agreement.
Covidien beats The Street, confirms 2012 guidance | Earnings Roundup
Covidien (NYSE:COV) beat Wall Street’s earnings expectations for both its fourth quarter and 2011 fiscal year, sending shares up 1.8 percent today.
The Mansfield, Mass.-based health care giant’s medical device segment once again led the charge, posting an 18 percent sales increase for Q4 and 17 percent for the full year.
Heart attack trials bring good news for Athersys
Athersys Inc. (NSDQ:ATHX) reported that results from a phase 1 trial of its stem cell therapy suggest its MultiStem technology could hold benefits for heart attack patients.
Stem cells: Athersys, Pfizer start MultiStem clinical trial for inflammatory bowel disease
Stem cell therapy developer Athersys (NSDQ:ATHX) and partner Pfizer (NYSE:PFE) have begun enrolling patients in a Phase II clinical trial for inflammatory bowel disease.
The trial marks an “important milestone” for Athersys because it’s the first time the company’s MultiStem treatment has advanced to a Phase II trial, CEO Gil Van Bokkelen said in a conference call with analysts to discuss the company’s quarterly financial numbers.
Athersys looks to raise $13.1 million in private offering
Stem cell company Athersys Inc. (NSDQ:ATHX) has reached an agreement to sell about $13 million of its shares to unidentified private investors.
Athersys will raise the cash by selling about 4.4 million shares of its common stock and warrants to purchase up to an additional 1.3 million shares, according to the company. Adding 5.7 million shares would increase the Cleveland company’s number of shares outstanding by 30 percent to about 25 million.
Athersys touts study findings on stem cell treatment for spinal injury
A new study shows Athersys Inc.’s (NSDQ:ATHX) stem cell technology could hold therapeutic benefits in treating spinal cord injuries.
Researchers found that administering Athersys’ MultiStem technology to rodents with spinal injuries reduced inflammation and promoted the regrowth of neurons, according to Athersys and the Case Western Reserve University School of Medicine.
Athersys wraps up enrollment for first phase of blood cancer study
Athersys Inc. (NSDQ:ATHX) has completed patient enrollment in the single-dose portion of a clinical trial that’s treating blood cancer patients with the company’s stem cell therapy.
